Clinical Trial

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-10.
Trial Details
NCT Number NCT06932861
Lead Sponsor Xinxin Zhang
Conditions Rhabdomyosarcoma
Enrollment 5 participants
Start Date 2025-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-22